Still Hope For Zetia Expansion After Negative Committee

 
• By Lisa LaMotta

An FDA Advisory Committee voted against an expanded approval for Merck & Co.'s cholesterol drug Zetia into a broader population. The negative vote may be a surprise to investors who thought the added label was a slam dunk, but anyone listening to the panel could’ve seen this negative vote coming.

The Endocrinologic and Metabolic drugs Advisory Committee voted 10 to 5 against expanding the label for Zetia (ezetimibe) to be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.